

### **Cautionary Statement Regarding Forward-Looking Statements**

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This presentation contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing exclusivity or trade marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; and the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation. Nothing in this presentation should be construed as a profit forecast.





**Pascal Soriot, Chief Executive Officer** 

AstraZeneca 📣

Simon Lowth, Chief Financial Officer

AstraZeneca 📣

## **Headline results 3Q 2012**

	2012 \$m	2011 \$m	Actual growth	CER growth
Revenue	6,682	8,213	-19%	-15%
Core Operating Profit	2,632	3,177	-17%	-14%
Core EPS	\$1.51	\$1.71	-12%	-8%
Restructuring	(\$0.15)	(\$0.12)		
MedImmune/Merck amortisation	(\$0.11)	(\$0.08)		
Intangible impairments	-	(\$0.01)		
Legal provisions/other	(\$0.03)	\$1.06		
Reported EPS	\$1.22	\$2.56	-53%	-50%



### Headline results 9Mo 2012

	2012 \$m	2011 \$m	Actual growth	CER growth
Revenue	20,691	24,935	-17%	-15%
Core Operating Profit	7,898	10,177	-22%	-20%
Core EPS	\$4.85	\$5.67	-14%	-11%
Restructuring MedImmune/Merck amortisation Intangible impairments Legal provisions/other	(\$0.71) (\$0.29) - (\$0.08)	(\$0.27) (\$0.24) (\$0.01) \$1.02		
Reported EPS	\$3.77	\$6.17	-39%	-36%
Net Share Repurchases	\$2,273	\$3,878		



## **Regional revenue performance 3Q 2012**


	2012 \$m	CER growth	CER \$m	
Global Revenue	6,682	-15%	(1,207)	Astra Tech/Aptium -1.8 pts
US	2,573	-19%	(614)	Seroquel IR (750) Ex-Seroquel IR +6%
Western Europe	1,461	-20%	(415)	Seroquel IR, Nexium, Atacand & Merrem generics
Established ROW	1,211	-18%	(272)	
Japan	723	-6%	(45)	
Canada	218	-43%	(174)	Crestor (153); Atacand (7)
Other Established ROW	270	-16%	(53)	
Emerging Markets	1,437	+6%	94	Mexico lowers growth rate by >2 pts
Emerging Europe	264	+4%	13	
China	399	+23%	73	
Emerging Asia Pacific	226	-4%	(9)	
Other Emerging ROW	548	+3%	17	Mexico -25%



## **Brand revenue performance 3Q 2012**

	2012 \$m	CER growth	CER \$m	
Global Revenue	6,682	-15%	(1,207)	
Crestor	1,544	-3%	(55)	Canada (153); ex-Canada +7%
Symbicort	785	+11%	84	
Seroquel XR	373	+8%	29	
Iressa	154	+11%	16	
Faslodex	167	+28%	39	
ONGLYZA™	84	+42%	25	
Brilinta/Brilique	24	+100%	13	
Nexium	995	-6%	(62)	Western Europe (56); Japan (52)
Seroquel IR	169	-83%	(856)	
Atacand	221	-34%	(122)	
Merrem	90	-29%	(40)	

### Crestor




#### 3Q 2012 Sales: \$1,544m -3%

#### US

- US TRx -3.3%
  - Statin market +0.9%
- Crestor volumes stable post generic atorvastatin



## Crestor : US net dynamic volume trend




Source: IMS NPA Market Dynamics, Data Week ending 09/21/2012

1 - Retail dynamic volumes only; does not include mail order or long term care business

2 - Volumes based on the 12 weeks of weekly data corresponding to each Quarter




## **Crestor:** US dynamic volume stable in Commercial and Part D segments, with erosion evident in Medicaid



Source: - IMS Xponent PlanTrak, Data Week ending 09/14/12

1 – Retail dynamic volumes only; does not include mail order or long term care business

### Crestor



#### 3Q 2012 Sales: \$1,544m -3%

#### US

- US TRx -3.3%
  - Statin market +0.9%
- Crestor volumes stable post generic atorvastatin

#### RoW

- RoW sales \$711m; -15%
  - Adj. for LOE in Canada; +2%




## **Brilinta: US launch progress**

#### Steady increase in key indicators

	4Q 2011	1Q 2012	2Q 2012	3Q 2012
Top 400: on Formulary	46%	68%	75%	79%
Top 400: on Protocol	14%	20%	32%	34%
IC Trial Overall	6%	15%	25%	34%
IC Trial when on Protocol	8%	20%	29%	39%
MM Overall Unrestricted Access	60%	61%	66%	69%
MM Part D Unrestricted Access	19%	27%	34%	48%


#### **Performance trend in TRxs**






## **Brilique: Strong Performance in Germany**


Hospital physicians reported *Brilique* on protocol in 82% of target hospitals through September, with 82% of these physicians trialing *Brilique*



## **Brilique: Performance in Nordic Region**



#### FINLAND: OAP Volume Market Share by Channel – Total



#### Launch dates:

Denmark: BRILINTA = Jan 2011; prasugrel = April 2009 Finland: BRILINTA = Feb 2011; prasugrel = May 2009 Norway: BRILINTA = Mar 2011; prasugrel = Jun 2009 Sweden: BRILINTA = Apr 2011; prasugrel = Sep 2009




7.1%

3.7%

Source: IMS Health MIDAS


SWEDEN: OAP Volume Market Share by Channel - Total



NORWAY: OAP Volume Market Share by Channel – Total


## **Brilique: Launch in Italy**

Hospital physicians reported *Brilique* on formulary in 61% of target hospitals through September, with 54% of these physicians trialing *Brilique*



### **ONGLYZA**<sup>™</sup>

#### 3Q 2012 Revenue: \$84m +42%



#### US

- TRx for DPP4s up 21% in 3Q
- AZ franchise share: 17.7% (Sept 2012)
  - ONGLYZA<sup>™</sup> share: 11.8%
  - KOMBIGLYZE XR<sup>™</sup> share: 5.9%

#### RoW

• RoW revenue \$22 million, +47%



## Core margin: 3Q 2012

	\$m	CER %	% sales	Delta vs PY CER
Revenue	6,682	-15%	-	
Core Gross Margin	5,422	-15%	81.1	-10 bps
Distribution	(90)	+2%	1.3	-20 bps
Core SG&A	(2,028)	-12%	30.3	-100bps
Core Other Income	416	+103%	6.2	+350 bps
Core Pre-R&D Profit	3,720	-11%	55.7	+220 bps
Core R&D	(1,088)	-3%	16.3	-190 bps
Core Operating Profit	2,632	-14%	39.4	+30 bps



## **Restructuring Programme: Phase 3 2012-14**

Total programme cost estimated at \$2.1 billion; most to be taken in 2012

	1Q	2Q	3Q	9Мо
Total	702	205	253	1,160
COGS	55	6	14	75
R&D	445	136	116	697
SG&A	202	63	123	388

Estimated annual benefits of \$1.6 billion by end 2014



## 9Mo 2012: Cash flow/distributions

Cash generated from operating activities \$4.1 billion (9Mo 2011 \$4.8 billion)

- Working capital management and lower tax payments, partially offset lower operating profit

Shareholder distributions

- Cash distributions \$5.9 billion YTD
- Net share repurchases
  - Net share repurchases 9Mo 2012: \$2.3 billion
  - Share repurchases suspended 1 October



## Guidance for 2012 (Core basis)

Revenue	Low to mid-teens decline at CER
Gross Margin	Below 2011, but above 80%
Pre-R&D Margin	Below 2011, but upper half of mid-term planning range
Net Finance Expense	In line with 2011
Other Operating Income	Low double-digit decline vs 2011; add back \$250m for <i>Nexium</i> OTC
Tax Rate	Effective reported tax rate around 20%
Core EPS	Maintained in the range \$6.00 to \$6.30



